Psychiatry & Pain

Which SSRI for Depression in Older Adults on Polypharmacy?

Quick answer

Sertraline and escitalopram are the preferred SSRIs in older adults with polypharmacy because of minimal CYP2D6/3A4 interactions and low anticholinergic burden. Avoid paroxetine (strong anticholinergic, potent 2D6 inhibitor) and fluoxetine (long half-life, strong 2D6 inhibitor). Start at half the usual adult dose and monitor sodium and QTc within 2–4 weeks.

Evidence review

Pivotal trials, effect sizes, and the populations they studied. PubMed identifiers link directly to the source.

Coupland et al. BMJ observational (2011)

PMID 21810886

60,746 adults ≥65 with depression

Paroxetine had higher adverse outcome rates than citalopram/sertraline. Falls (HR 1.36), fractures (HR 1.27), hyponatremia all higher vs sertraline.

Practical decision algorithm

IfThen
Major depression, age ≥65, polypharmacyStart sertraline 25 mg daily or escitalopram 5 mg daily; titrate every 2 weeks.
Concurrent warfarin, DOAC, or antiplateletPrefer sertraline or mirtazapine (lower GI bleed risk than paroxetine/fluoxetine). Add PPI if concomitant NSAID.
Concurrent tamoxifenAvoid paroxetine and fluoxetine (inhibit 2D6 conversion to endoxifen). Use escitalopram or venlafaxine.
Baseline QTc >450 ms or on other QT-prolonging agentsAvoid citalopram >20 mg/day. Prefer sertraline.
Hyponatremia on initiationCheck sodium at 2 and 4 weeks. SIADH risk 1–2%; manage with fluid restriction or switch to mirtazapine.

Guideline position

APA 2019 Clinical Practice Guideline for Treatment of Depression (older adults cohort): second-generation antidepressants including SSRIs recommended for MDD in older adults; sertraline and escitalopram are commonly preferred for their interaction and tolerability profile. AGS Beers Criteria 2023: paroxetine is potentially inappropriate in older adults due to strong anticholinergic effects.

Contraindications and cautions

  • Concurrent MAOI within 14 days
  • Severe hepatic impairment (dose-adjust escitalopram)
  • Active mania or unstable bipolar disorder
  • QTc >500 ms (citalopram especially)
  • Serotonin syndrome risk with MAOI, tramadol, linezolid combinations

Frequently asked questions

How does GI bleeding risk compare between SSRIs?
Risk is roughly doubled across SSRIs (and raised fivefold with concurrent NSAID), but absolute risk remains low. Add a PPI when NSAID or antiplatelet co-prescribed.
Is mirtazapine a reasonable alternative?
Yes. Mirtazapine avoids GI bleed amplification, promotes weight gain and sleep, and lacks significant CYP interactions. Sedation and orthostasis limit daytime dosing.
When should I check sodium?
Baseline and at 2 and 4 weeks. Further checks with dose changes, acute illness, or new diuretic. Elderly thin women on thiazides are highest risk.
How long to wait before switching for inadequate response?
6–8 weeks at therapeutic dose. Older adults often need longer. If no response, cross-taper to a different SSRI/SNRI or add augmentation.
Do SSRIs worsen cognition in dementia?
Evidence is mixed. Sertraline and escitalopram are cognitively neutral. Avoid paroxetine — its anticholinergic burden worsens cognition and raises delirium risk.

Further reading

Clinical Reasoning

Polypharmacy in Elderly Patients: An Evidence-Based Deprescribing Framework

Methodology

Treatment-Resistant Depression: Augmentation Strategies and Emerging Therapies

Methodology

Major Depressive Disorder in Adolescents: SSRI Selection, Monitoring, and Suicidality Risk

Back to all decision points